EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers

Angélica Ramos iD, Sandra Martins iD, Ana Sofia Marinho, Pedro Norton, Maria João Cardoso, João Tiago Guimarães

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0303244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Angélica Ramos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Patologia Clínica, Centro Hospitalar Universitário de São João, Porto, Portugal. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19, Health Personnel, Interferon-gamma Release Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To predict protective immunity to SARS-CoV-2, cellular immunity seems to be more sensitive than humoral immunity. Through an Interferon-Gamma (IFN-γ) Release Assay (IGRA), we show that, despite a marked decrease in total antibodies, 94.3% of 123 healthcare workers have a positive cellular response 6 months after inoculation with the 2nd dose of BNT162b2 vaccine. Despite the qualitative relationship found, we did not observe a quantitative correlation between IFN-γ and IgG levels against SARS-CoV-2. Using stimulated whole blood from a subset of participants, we confirmed the specific T-cell response to SARS-CoV-2 by dosing elevated levels of the IL-6, IL-10 and TNF-α. Through a 20-month follow-up, we found that none of the infected participants had severe COVID-19 and that the first positive cases were only 12 months after the 2nd dose inoculation. Future studies are needed to understand if IGRA-SARS-CoV-2 can be a powerful diagnostic tool to predict future COVID-19 severe disease, guiding vaccination policies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-19Health PersonnelInterferon-gamma Release TestsSARS-CoV-2AdultFemaleHumansMaleMiddle AgedAntibodies, ViralCOVID-19 VaccinesImmunity, CellularImmunoglobulin GInterferon-gammaInterleukin-10Interleukin-6Tumor Necrosis Factor-alphaVaccination

Substanzen

Antibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GInterferon-gammaInterleukin-10Interleukin-6Tumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Serviço de Patologia Clínica, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • EPIUnit-Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
  • Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Universidade do Porto, Porto, Portugal.
  • Serviço de Saúde Ocupacional, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Departamento de Biomedicina, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.

ORCID-Profile: Angélica Ramos, Sandra Martins

Förderung

  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Ramos, A., Martins, S., Marinho, A. S., Norton, P., Cardoso, M. J., & Guimarães, J. T. (2024). Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers. PLOS ONE. https://doi.org/10.1371/journal.pone.0303244

Vancouver

Ramos A, Martins S, Marinho AS, Norton P, Cardoso MJ, Guimarães JT. Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers. PLOS ONE. 2024. doi:10.1371/journal.pone.0303244

BibTeX
@article{Ramos2024,
  author = {Ramos, Angélica and Martins, Sandra and Marinho, Ana Sofia and Norton, Pedro and Cardoso, Maria João and Guimarães, João Tiago},
  title = {Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0303244}
}
Kostenlos starten →